Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

WASHINGTON – People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results ...

John Comerford, senior partner of Lipsitz, Ponterio & Comerford says when people come to see them with mesothelioma, they have to do a little type of investigation to determine how they were exposed ...

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural ...

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to U.S. Food and Drug Administration approvals and changes in the standard of care with a ...

SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, ...

The Internet of Things (IoT) is stepping out of Sci-Fi movies and entering our daily lives, ready to fight even the most difficult conditions, like cancer. From simple devices such as the Fitbit band ...

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a ...